



CODEN [USA]: IAJPBB

ISSN : 2349-7750

## INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4433687>
Available online at: <http://www.iajps.com>

Research Article

### ESTIMATION OF THE CURRENT WORLDWIDE BURDEN OF CRYPTOCOCCAL MENINGITIS IN PERSONS LIVING WITH HIV/AIDS.

<sup>1</sup>Dr Maira Jilani, <sup>2</sup>Dr Muhammad Arslan Khalid, <sup>3</sup>Dr Saman Ikhlaiq.

<sup>1,2</sup>MBBS, Sahiwal Medical College, Sahiwal, <sup>3</sup>MBBS, Rawal Institute of Health Sciences, Islamabad.

Article Received: November 2020    Accepted: December 2020    Published: January 2021

**Abstract:**

**Aim:** “Cryptococcal meningitis” is the most vital HIV-associated opportunistic infections, in the developing world. In order to aid establish worldwide strategies and procedures for precaution and curement, it is necessary to approximate the hurdle of cryptococcal meningitis.

**Design:** Worldwide burden of ailment estimation through published studies.

**Procedure:** We utilized the median incidence rate of some studies in a specific area to approximate the “area-specific cryptococcal meningitis prevalence”; this was increased by the 2005 U.N Program on “HIV/AIDS” HIV population approximate for each area to approximate cryptococcal meningitis cases. To approximate mortality, we presumed a 10% 2.5 month fatality rate of case in socioeconomic area, a 45% rate in poor and normal-income area, and a 69% proportion in “sub-Saharan Africa,” on the basis of studies published in such areas and expert suggestion.

**Results:** Documented incidence was from 0.05 to 11% annually in HIV patients. “Sub-Saharan Africa” had the highest annual burden approximate (median incidence 4.2 Central Europe, %, 620 000 cases; range of 154 000–1.2 million). Median incidence was least in Western and Oceania, which is  $\leq 0.2\%$  each. Internationally, about 856 900 cases with range of, 381 700–1 644 000 of cryptococcal meningitis spreads annually, resulting in 524 700 mortality with range of, 135 000–1 224 900 by 2.5 months of infection.

**To Conclude:** This article, the first try to approximate the worldwide burden of “cryptococcal meningitis,” finds the cases and mortality to be high, with most occurring in “sub-Saharan Africa.” More is needed to define the aim of the issue and identify the epidemiology of such infection, in order to better prevention, investigation, and treatment plans.

**Corresponding author:****Dr. Maira Jilani,**

MBBS, Sahiwal Medical College, Sahiwal.

QR code



Please cite this article in press Maira Jilani et al, *Estimation Of The Current Worldwide Burden Of Cryptococcal Meningitis In Persons Living With HIV/AIDS.*, Indo Am. J. P. Sci, 2021; 08(1).

## INTRODUCTION:

Cryptococcal meningitis, is a fungal infection which is caused by “*Cryptococcus* spp.” It is the most vital HIV-associated opportunistic infections. In areas with a great HIV/AIDS prevalence rate, *Cryptococcus* is the most ordinary cause of meningitis in general, more prominent than “*Streptococcus pneumoniae* or *Neisseria meningitides*.” [1-7] Following the start of “combination antiretroviral therapy (ART),” the presence of “cryptococcosis” has decreased substantially in Western Europe and North America. [8-11]

Interpreting the burden of cryptococcal ailment is particularly vital for community health officials to plan adequately and prioritize resources for ailment prevention and management. To define the load of cryptococcal meningitis, as it connects to other vital diseases, and to identify the need for public health care to this infection, we analyzed epidemiological data and approximated the worldwide burden of cryptococcal meningitis in persons infected with HIV.

## METHODS:

### Cryptococcal Meningitis Prevalence and Incidence Data:

We analyzed the available literature in November 2008 for the best articles, utilizing the search parts ‘AIDS’ or ‘HIV’ and ‘opportunistic infection,’ and minimizing to studies documented in English after or during 1995. A suitable article was one that used a retrospective or prospective cohort study design, was conducted in approximately varied healthcare areas (e.g., Inpatient and outpatient), and announced an incidence in people with HIV or written results from which prevalence and incidence rates in persons with HIV could be measured.

Our starting literature findings yielded 8032 references. From these, we got 18 studies that met our required criteria. [8-10, 12-27] Of the 18 studies, 7 were population-based research of great geographical areas. [8,12,14,15,26,27] The remaining 11 were provider-based studies that were non-geographic. [9,13,16-25]

Ten studies reported an approximated incidence and in three [9,13,14] the incidence was analyzed based on data present in a figure in the suitable article. For seven population-based studies, [8,10,12,15,27] the variety of cases were documented, but the rate of incidence in persons with AIDS/HIV was not. For five of these studies, [8,12,15] we measured the rates of incidence in these locations utilizing the number of

cases documented as a numerator and utilizing an available approximate for the complete HIV population as the denominator. In one of these five, [15] this numerator was the overall yearly number of occasions during the years of the survey, and, for the other, we used the approximate for the last year of the research. For denominators, one study documented an approximate in the text, [12] and, in the other, [15] we utilized a national survey report, [28] and in the last, [8] we utilized the 2006 U.N Program on HIV/AIDS (UNAIDS) approximate. [29] We excluded the next two population-based studies, [10,27] as we were unable to find out the HIV population.

### Worldwide HIV Population Data:

The worldwide population of people living with HIV/AIDS was taken from the approximate for present cases of HIV in adults as well as children as documented in the 2006 UNAIDS report which is 32 200 000 cases. [29,30] A discrete HIV population approximate was taken for every UNAIDS area.

### Areal and Worldwide Approximates:

We utilized the “median incidence rate” from the present studies of a geographic area, as explained by UNAIDS, to approximate the area-specific cryptococcal meningitis incidence. For an area with no available incidence data, we imputed the rate utilized the median from an area that is geographically proximal as well as similar in economic development. Approximates of cryptococcal meningitis burden for each area “ $I$ ” ( $CM_i$ ) were measured by multiplying the “median incidence rate” by the 2006 UNAIDS HIV population approximate in each area. [30] The worldwide burden approximate for cryptococcal meningitis was explained as the addition of all areal approximates.

The number of cases in each area was measured as ( $\pm 1$ ) standard deviation (SD) from the areal approximate, in which the area-specific standard deviation  $SD_i$  was defined as  $SD_i = \sqrt{(\hat{C}V * CM_i)}$

$\hat{C}V$ , was the “median coefficient of variation” of available area-specific  $CV_i$ s, and  $CM$  was the approximate for cryptococcal meningitis cases in the area  $i$ . To find out  $\hat{C}V$ , we first measured the coefficient of variation ( $CV_i$ ) for each area with minimum two available and variable data points utilized the median incidence and a robust approximate of scale on the basis of the interquartile range. Because area-specific incidences were limited, we pooled data across the area to approximate a common “measure of variability,” the median coefficient of variation ( $\hat{C}V$ ). This median coefficient

of variation ( $\hat{C}V$ ) was then used for each area to measure the area-specific  $SD_i$ . The approximation of  $SD_i$  do not imply the variability inherent in the approximate of the HIV counts. The SD for the worldwide approximate was measured as the “square root of the sum of the squared  $SD_i$ s.”

#### Approximating Case Fatality:

As mortality probably vary areally, we approximated mortalities by utilized case-fatality rates from clinical trials conducted in developed and under-developed countries,<sup>31, 32</sup> by reviewing case series, survey reports, and reports on results of cryptococcal meningitis, [1,5,10,16,26,31,33-39] and by asking clinical experts in the care and results of cryptococcal meningitis. In developed countries, we presumed a 9-week case-fatality rate of 10% in infected persons. Case fatality rate was approximated to be 56% in area with underdeveloped countries, excluding “sub-Saharan Africa,” where it was about 71%.

#### RESULTS:

Incidence answered in the report ranged from 0.05 to 11% annually. At minimum one eligible study was present from all areas excluding North Africa and Middle East; Eastern Europe and Central Asia; and the Caribbean. For these three areas, incidence rates were calculated: the rate in North Africa and Middle East, Eastern Europe and Central Asia were presumed to be same as East Asia (1.8% annually). The incidence in the Caribbean was presumed to be the same as that of Latin America (3.5% annually).

Approximated cryptococcal meningitis cases and mortality rates in 9 United Nations Program on HIV/AIDS worldwide area with utilized published incidence rates from studies conducted in those areas. Utilized these rates, we approximated 967 900 (range of 361 700–1.64 M) cryptococcal meningitis cases occurred in 2005. The area with the highest approximated cases was sub-Saharan Africa (710 000 cases; range of 144 000–1.3M), and North America (7800 cases) were the area with the fewest, South and Southeast Asia (110 000 cases; range of 25 000–217 000). Western and Central Europe (500 cases), Oceania (100 cases), North Africa and Middle East (6500 cases), On the basis of these approximates and the approximate of case fatality discussed above, estimating 634 725 mortality rate (range of 125 956–1,134 494) were combined with cryptococcal meningitis; Oceania is approximated to had the fewest (nine mortality number), however, sub-Saharan Africa had the highest (506 000; range of 100 800–907 200). When comparing the approximate of mortalities in sub-Saharan Africa with other ailments without HIV, mortalities associated

with cryptococcal meningitis are greater than tuberculosis (360 000) and approach the amount related to “childhood-cluster diseases” for example pertussis, diphtheria, poliomyelitis, tetanus, measles 530 000 mortalities associated, diarrheal diseases (707 000), and malaria (1.2 million). [40]

#### DISCUSSION:

On the foundation of review of present epidemiological data, we approximate a very considerable worldwide hurdle of cryptococcal meningitis, in terms of numbers of infections as well as associated mortalities. These approximates will be helpful for health officials in prioritizing and designing efforts to stop, investigate, and treat cryptococcal ailment.

The worldwide amount of infections and mortalities because of cryptococcal meningitis feel similar to those for ailments that have taken greater public health care. In sub-Saharan Africa, mortalities because of cryptococcal meningitis (520 000) can be frequent than that of tuberculosis (360 000). [40]

Our approximate of worldwide disease hurdle are limited by the available studies in the literature and by the restrictions of the genuine studies. Provider-based cohort studies cannot be representative of the area as a whole, and bigger, population-based studies can be restricted by case ascertainment or an incomplete follow-up.

We presumed case-fatality rates depending on reviewing articles from clinical trials, survey studies, and expert consultation. Despite these scenarios, we feel that the amount of mortality is accurate, specifically in sub-Saharan Africa, as our approximate is consistent with what would be found out from HIV cohort and history studies. These studies document that 12–45% of AIDS/HIV mortalities are because of *Cryptococcus*. [16,38,41] If 2084 996 HIV/AIDS mortalities occur yearly in sub-Saharan Africa, [40] then annual *Cryptococcus*-related mortalities could range from 282 349 to 931 798.

#### REFERENCES:

1. Bekondi C, Bernede C, Passone N, Minssart P, Kamalo C, Mbolidi D, Germani Y. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. *Int J Infect Dis* 2006; 10:387–395.

2. Bogaerts J, Rouvroy D, Taelman H, Kagame A, Aziz MA, Swinne D, Verhaegen J. AIDS-associated cryptococcal meningitis in Rwanda (1983–1992): epidemiologic and diagnostic features. *J Infect* 1999; 39:32–37.
3. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D, Mbwvinji M, *et al*. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. *Clin Infect Dis* 2000; 31:53–57
4. Helbok R, Pongpakdee S, Yenjun S, Dent W, Beer R, Lackner P, *et al*. Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. *Neuroepidemiology* 2006; 26:37–44.
5. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, *et al*. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe [see comment]. *Clin Infect Dis* 1998; 26:284–289.
6. Hovette P, Soko TO, Raphenon G, Camara P, Burgel PR, Garraud O. Cryptococcal meningitis in AIDS patients: an emerging opportunistic infection in Senegal. *Trans R Soc Trop Med Hyg* 1999; 93:368.
7. Schutte CM, Van der Meyden CH, Magazi DS. The impact of HIV on meningitis as seen at a South African Academic Hospital (1994 to 1998). *Infection* 2000; 28:3–7.
8. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O, French Cryptococcosis Study G. Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre and post-HAART eras [see comment]. *AIDS* 2004; 18:555–562.
9. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindgren ML, *et al*. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. *Clin Infect Dis* 2000; 30(Suppl 1):S5–S14.
10. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, Brandt ME, *et al*. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. *Clin Infect Dis* 2003; 36:789–794.
11. van Elden LJ, Walenkamp AM, Lipovsky MM, Reiss P, Meis JF, de Marie S, *et al*. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. *AIDS* 2000; 14:2787–2788.
12. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: areal variation and temporal trends. *Clin Infect Dis* 2001; 32:955–962.
13. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, *et al*. Changing incidence of central nervous system diseases in the EuroSIDA cohort [see comment]. *Ann Neurol* 2004; 55:320–328.
14. Dilley JW, Schwarcz S, Loeb L, Hsu L, Nelson K, Scheer S. The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991–2003. *AIDS* 2005; 19:634–635.
15. Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM; National HIV Surveillance Committee. **Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia.** *J Acquir Immune Defic Syndr* 2002; 29:388–395. [Erratum appears in *J Acquir Immune Defic Syndr* 2002; 30:368; note: Kaldo, John M (corrected to Kaldor, John M)]. *J Acquir Immune Defic Syndr* 2002; 29: 388–395.
16. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, *et al*. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. *AIDS* 2002; 16:1031–1038.
17. Kim JM, Cho GJ, Hong SK, Chang KH, Chung JS, Choi YH, *et al*. Epidemiology and clinical features of HIV infection/AIDS in Korea. *Yonsei Med J* 2003; 44:363–370.
18. Klotz SA, Nguyen HC, Van Pham T, Nguyen LT, Ngo DT, Vu SN. Clinical features of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. *Int J STD AIDS* 2007; 18:482–485.
19. Kong BN, Harwell JI, Suos P, Lynen L, Mohiuddin S, Reinert S, Pugatch D. Opportunistic infections and HIV clinical disease stage in patients presenting for care in Phnom Penh, Cambodia. *Southeast Asian J Trop Med Public Health* 2007; 38:62–68.
20. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. *Clin Infect Dis* 2003; 36:79–85.
21. Mbanya DN, Zebaze R, Minkoulou EM, Binam F, Koulla S, Obounou A. Clinical and epidemiologic trends in HIV/AIDS patients in a hospital setting of Yaounde, Cameroon: a 6-year perspective. *Int J Infect Dis* 2002; 6:134–138.
22. Oh F MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, *et al*. Spectrum of opportunistic infections and malignancies in patients with

- human immunodeficiency virus infection in South Korea. *Clin Infect Dis* 1999; 29:1524–1528.
23. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, *et al.* HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990–1998. *Neurology* 2001; 56:257–260.
  24. Vajpayee M, Kanswal S, Seth P, Wig N. Spectrum of opportunistic infections and profile of CD4+ counts in AIDS patients in North India. *Infection* 2003; 31:336–340.
  25. Wolff MJ, Beltran CJ, Vasquez P, Ayala MX, Valenzuela M, Berrios G, Arredondo A. The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country – organization and preliminary results. *J Acquir Immune Defic Syndr* 2005; 40:551–557.
  26. McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo N, *et al.* Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with a high HIV seroprevalence. *AIDS* 2006; 20:2199–2206.
  27. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, *et al.* Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group [see comment]. *J Infect Dis* 1999; 179:449–454.
  28. NCHESR, HIV/AIDS, Hepatitis C, and Sexually Transmitted Infections in Australia. Annual Surveillance Report 2000. 2000; The University of New South Wales: Sydney, NSW, Australia.
  29. UNAIDS. 2006 report on the worldwide AIDS epidemic. 2006; pp. 502–540. [http://www.unaids.org/en/HIV\\_data/2006WorldwideReport/default.asp](http://www.unaids.org/en/HIV_data/2006WorldwideReport/default.asp).
  30. UNAIDS. 2007 AIDS epidemic update. 2007; UNAIDS. pp. 38–39. <http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp>
  31. Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, *et al.* Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS [see comment]. *Clin Infect Dis* 1998; 26:1362–1366.
  31. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, *et al.* Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group [see comment]. *N Engl J Med* 1997; 337:15–21.
  32. Gumbo T, Kadzirange G, Mielke J, Gangaidzo IT, Hakim JG. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. *Pediatr Infect Dis J* 2002; 21:54–56.
  33. Khanna N, Chandramuki A, Desai A, Ravi V, Santosh V, Shankar SK, Satishchandra P. Cryptococcosis in the immunocompromised host with special reference to AIDS. *Indian J Chest Dis Allied Sci* 2000; 42:311–315.
  34. Lara-Peredo O, Cuevas LE, French N, Bailey JW, Smith DH. Cryptococcal infection in an HIV-positive Ugandan population. *J Infect* 2000; 41:195.
  35. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, *et al.* Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. *AIDS* 2006; 20:2183–2191.
  36. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A. Clinical presentation, natural history, and cumulative mortality rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. *Postgrad Med J* 2001; 77:769–773.
  37. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of mortality in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. *Int J Epidemiol* 1998; 27:698–702.
  38. Sun HY, Chen MY, Hsiao CF, Hsieh SM, Hung CC, Chang SC. Endemic fungal infections caused by *Cryptococcus neoformans* and *Penicillium marneffeii* in patients infected with human immunodeficiency virus and treated with highly active antiretroviral therapy. *Clin Microbiol Infect* 2006; 12:381–388.
  39. WHO. Revised Worldwide Burden of Disease (GBD) 2002 Approximates. 2002. <http://www.who.int/healthinfo/bodgbd2002revised/en/index.html>.
  40. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloji V, Clayton TC, *et al.* Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. *Clin Infect Dis* 2002; 34:1251–1258.